Union Jobs Report
PILMA news
United Association President McManus Letter to HELP Committee
September 25, 2024 To:The Office of Senator Bernie Sanders, ChairU.S. Senate Committee on Health, Education, Labor, and Pensions332 Dirksen Senate Office Bldg. Washington, D.C., 20510 The Office of Senator Bill Cassidy, Ranking MemberU.S. Senate Committee on Health, Education, Labor, and Pensions455 Dirksen Senate Office Bldg.Washington, D.C., 20510 cc: Members of
STATEMENT CONCERNING CMS’ Announcement of 10 Drugs Selected for 2026 Government Price Controls
August 13, 2024Today, the Centers for Medicare and Medicaid Services (CMS) released the Maximum Fair Prices (MFPs) for 10 selected medicines to go into effect in 2026. PILMA reiterates our opposition to MFPs, which are simply government price controls on medicines in Medicare under the guise of negotiation. PILMA has
STATEMENT Supporting the House Oversight Committee Hearings on PBM Transparency and Accountability
July 23, 2024 The labor and industry partners of the Pharmaceutical Industry Labor- Management Association (PILMA) applaud the House Oversight Committee’s investigation into the role of PBMs in prescription drug markets. PILMA has a long history of supporting increased transparency and accountability in the prescription drug supply chain and has
THE MIDDLEMEN: The Opaque Industry Secretly Inflating Prices for Prescription DrugsPharmacy benefit managers are driving up drug costs for millions of people, employers and the government.
By Rebecca Robbins and Reed Abelson This is the first article in a series about how pharmacy benefit managers prioritize their interests, often at the expense of patients, employers and taxpayers. Americans are paying too much for prescription drugs. It is a common, longstanding complaint. And the culprits seem obvious: Drug companies. Insurers.
Facility Tours
Resolutions
Reports
